SpyGlass Pharma Inc (SGP) Stock Analysis

Verdict: WATCH (do not buy)

Deep cash runway funds Phase 3 BIM-IOL trials into 2028, but pre-revenue clinical binary risks and EPS misses warrant patience.

Investment score: 48/100

Analysis as of

Is SpyGlass Pharma Inc stock worth reviewing? The TradeMates thesis

SpyGlass Pharma possesses a funded runway through 2028 following its $172.5M IPO and holds strong clinical Phase 1/2 data for its drug-eluting IOL system. However, as a pre-revenue biotech trading 26% off its 52-week highs with recent earnings misses, the model sees a neutral risk-reward balance until Phase 3 enrollment milestones approach.

7-factor investment score

SpyGlass Pharma Inc opportunities and risks

What speaks for SGP

What speaks against SGP

Peers and competitors

Trailing-twelve-month ratios
TickerP/EP/SEV/EBITDAGross marginNet marginFCF yield
SGPn/a0.0xn/a0.0%0.0%-6.2%
SPTXn/a0.0xn/a0.0%0.0%-4.9%
ANROn/a0.0xn/a0.0%0.0%-8.0%
ALMSn/a107.1xn/a88.2%-5933.5%-44.4%
COLL15.2x0.9x3.1x60.0%5.9%43.5%
Peer mediann/a0.5xn/a30.0%0.0%-6.4%

Frequently asked questions about SpyGlass Pharma Inc (SGP)

Is SGP stock a good investment?

The TradeMates model rates SpyGlass Pharma Inc as WATCH (do not buy) with an investment score of 48/100. SpyGlass Pharma possesses a funded runway through 2028 following its $172.5M IPO and holds strong clinical Phase 1/2 data for its drug-eluting IOL system. However, as a pre-revenue biotech trading 26% off its 52-week highs with recent earnings misses, the model sees a neutral risk-reward balance until Phase 3 enrollment milestones approach. This is algorithmic model output, not personal investment advice.

Is SGP stock a buy?

The TradeMates model verdict for SGP is WATCH (do not buy) with an investment score of 48/100. Treat this as a model signal to review, not a personal buy recommendation.